People have the right to be involved in discussions and make informed decisions about their care, as described in your care.
Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.
184.108.40.206 Refer for specialist opinion any person with suspected persistent synovitis of undetermined cause. Refer urgently if any of the following apply:
the small joints of the hands or feet are affected
more than one joint is affected
there has been a delay of 3 months or longer between onset of symptoms and seeking medical advice. 
220.127.116.11 Refer urgently any person with suspected persistent synovitis of undetermined cause, even if their blood tests show a normal acute-phase response or negative rheumatoid factor. 
18.104.22.168 Offer to carry out a blood test for rheumatoid factor in people with suspected RA who are found to have synovitis on clinical examination. 
22.214.171.124 Consider measuring anti-cyclic citrullinated peptide (CCP) antibodies in people with suspected RA if:
they are negative for rheumatoid factor, and
there is a need to inform decision-making about starting combination therapy (see 126.96.36.199). 
188.8.131.52 X-ray the hands and feet early in the course of the disease in people with persistent synovitis in these joints. 
184.108.40.206 Explain the risks and benefits of treatment options to people with RA in ways that can be easily understood. Throughout the course of their disease, offer them the opportunity to talk about and agree all aspects of their care, and respect the decisions they make. 
220.127.116.11 Offer verbal and written information to people with RA to:
improve their understanding of the condition and its management, and
counter any misconceptions they may have. 
18.104.22.168 People with RA who wish to know more about their disease and its management should be offered the opportunity to take part in existing educational activities, including self-management programmes. 
22.214.171.124 People with RA should have ongoing access to a multidisciplinary team. This should provide the opportunity for periodic assessments (see 126.96.36.199 and 188.8.131.52) of the effect of the disease on their lives (such as pain, fatigue, everyday activities, mobility, ability to work or take part in social or leisure activities, quality of life, mood, impact on sexual relationships) and help to manage the condition. 
184.108.40.206 People with RA should have access to specialist physiotherapy, with periodic review (see 220.127.116.11 and 18.104.22.168), to:
improve general fitness and encourage regular exercise
learn exercises for enhancing joint flexibility, muscle strength and managing other functional impairments
learn about the short-term pain relief provided by methods such as transcutaneous electrical nerve stimulators [TENS] and wax baths. 
22.214.171.124 People with RA should have access to specialist occupational therapy, with periodic review (see 126.96.36.199 and 188.8.131.52), if they have:
difficulties with any of their everyday activities, or
problems with hand function. 
184.108.40.206 Offer psychological interventions (for example, relaxation, stress management and cognitive coping skills) to help people with RA adjust to living with their condition. 
220.127.116.11 All people with RA and foot problems should have access to a podiatrist for assessment and periodic review of their foot health needs (see 18.104.22.168 and 22.214.171.124). 
126.96.36.199 Functional insoles and therapeutic footwear should be available for all people with RA if indicated. 
188.8.131.52 Consider a tailored strengthening and stretching hand exercise programme for people with RA with pain and dysfunction of the hands or wrists if:
they are not on a drug regimen for RA, or
they have been on a stable drug regimen for RA for at least 3 months. [new 2015]
184.108.40.206 The tailored hand exercise programme for people with RA should be delivered by a practitioner with training and skills in this area. [new 2015]
220.127.116.11 In people with newly diagnosed active RA, offer a combination of DMARDs (including methotrexate and at least one other DMARD, plus short-term glucocorticoids) as first-line treatment as soon as possible, ideally within 3 months of the onset of persistent symptoms. 
18.104.22.168 Consider offering short-term treatment with glucocorticoids (oral, intramuscular or intra-articular) to rapidly improve symptoms in people with newly diagnosed RA if they are not already receiving glucocorticoids as part of DMARD combination therapy. 
22.214.171.124 In people with recent-onset RA receiving combination DMARD therapy and in whom sustained and satisfactory levels of disease control have been achieved, cautiously try to reduce drug doses to levels that still maintain disease control. 
126.96.36.199 In people with newly diagnosed RA for whom combination DMARD therapy is not appropriate, start DMARD monotherapy, placing greater emphasis on fast escalation to a clinically effective dose rather than on the choice of DMARD. 
188.8.131.52 In people with established RA whose disease is stable, cautiously reduce dosages of disease-modifying or biological drugs. Return promptly to disease-controlling dosages at the first sign of a flare. 
184.108.40.206 When introducing new drugs to improve disease control into the treatment regimen of a person with established RA, consider decreasing or stopping their pre-existing rheumatological drugs once the disease is controlled. 
220.127.116.11 In any person with established rheumatoid arthritis in whom disease-modifying or biological drug doses are being decreased or stopped, arrangements should be in place for prompt review. 
18.104.22.168 Offer short-term treatment with glucocorticoids for managing flares in people with recent-onset or established disease to rapidly decrease inflammation. 
22.214.171.124 In people with established RA, only continue long-term treatment with glucocorticoids when:
the long-term complications of glucocorticoid therapy have been fully discussed, and
all other treatment options (including biological drugs) have been offered. 
Please see our web page on arthritis for other NICE technology appraisal guidance on biological drugs for RA.
126.96.36.199 On the balance of its clinical benefits and cost effectiveness, anakinra is not recommended for the treatment of RA, except in the context of a controlled, long-term clinical study. 
188.8.131.52 Patients currently receiving anakinra for RA may suffer loss of wellbeing if their treatment were discontinued at a time they did not anticipate. Therefore, patients should continue therapy with anakinra until they and their consultant consider it is appropriate to stop. 
184.108.40.206 Do not offer the combination of tumour necrosis factor-α (TNF-α) inhibitor therapy and anakinra for RA. 
Recommendations 220.127.116.11–18.104.22.168 in this section replace the rheumatoid arthritis aspects only of 'Guidance on the use of cyclo-oxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis' (NICE technology appraisal guidance 27). They are adapted from the NICE guideline on osteoarthritis: the care and management of osteoarthritis in adults (CG59).
22.214.171.124 Offer analgesics (for example, paracetamol, codeine or compound analgesics) to people with RA whose pain control is not adequate, to potentially reduce their need for long-term treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or cyclo-oxygenase-2 (COX-2) inhibitors. 
126.96.36.199 Oral NSAIDs/COX-2 inhibitors should be used at the lowest effective dose for the shortest possible period of time. 
188.8.131.52 When offering treatment with an oral NSAID/COX-2 inhibitor, the first choice should be either a standard NSAID or a COX-2 inhibitor. In either case, these should be co‑prescribed with a proton pump inhibitor (PPI), choosing the one with the lowest acquisition cost. 
184.108.40.206 All oral NSAIDs/COX-2 inhibitors have analgesic effects of a similar magnitude but vary in their potential gastrointestinal, liver and cardio-renal toxicity; therefore, when choosing the agent and dose, healthcare professionals should take into account individual patient risk factors, including age. When prescribing these drugs, consideration should be given to appropriate assessment and/or ongoing monitoring of these risk factors. 
220.127.116.11 If a person with RA needs to take low-dose aspirin, healthcare professionals should consider other analgesics before substituting or adding an NSAID or COX-2 inhibitor (with a PPI) if pain relief is ineffective or insufficient. 
18.104.22.168 If NSAIDs or COX-2 inhibitors are not providing satisfactory symptom control, review the disease-modifying or biological drug regimen. 
22.214.171.124 Measure CRP and key components of disease activity (using a composite score such as DAS28) regularly in people with RA to inform decision-making about:
increasing treatment to control disease
cautiously decreasing treatment when disease is controlled. 
126.96.36.199 In people with recent-onset active RA, measure CRP and key components of disease activity (using a composite score such as DAS28) monthly until treatment has controlled the disease to a level previously agreed with the person with RA. 
188.8.131.52 Offer people with satisfactorily controlled established RA review appointments at a frequency and location suitable to their needs. In addition, make sure they:
have access to additional visits for disease flares,
know when and how to get rapid access to specialist care, and
have ongoing drug monitoring. 
184.108.40.206 Offer people with RA an annual review to:
assess disease activity and damage, and measure functional ability (using, for example, the Health Assessment Questionnaire [HAQ])
check for the development of comorbidities, such as hypertension, ischaemic heart disease, osteoporosis and depression
assess symptoms that suggest complications, such as vasculitis and disease of the cervical spine, lung or eyes
organise appropriate cross referral within the multidisciplinary team
assess the need for referral for surgery (see section 1.6)
assess the effect the disease is having on a person's life. 
220.127.116.11 Offer to refer people with RA for an early specialist surgical opinion if any of the following do not respond to optimal non-surgical management:
persistent pain due to joint damage or other identifiable soft tissue cause
worsening joint function
persistent localised synovitis. 
18.104.22.168 Offer to refer people with any of the following complications for a specialist surgical opinion before damage or deformity becomes irreversible:
imminent or actual tendon rupture
nerve compression (for example, carpal tunnel syndrome)
stress fracture. 
22.214.171.124 When surgery is offered to people with RA, explain that the main expected benefits are:
improvement, or prevention of further deterioration, of joint function, and
prevention of deformity. 
126.96.36.199 Offer urgent combined medical and surgical management to people with RA who have suspected or proven septic arthritis (especially in a prosthetic joint). 
188.8.131.52 If a person with RA develops any symptoms or signs that suggest cervical myelopathy:
request an urgent MRI scan, and
refer for a specialist surgical opinion. 
184.108.40.206 Do not let concerns about the long-term durability of prosthetic joints influence decisions to offer joint replacements to younger people with RA. 
220.127.116.11 Inform people with RA who wish to experiment with their diet that there is no strong evidence that their arthritis will benefit. However, they could be encouraged to follow the principles of a Mediterranean diet (more bread, fruit, vegetables and fish; less meat; and replace butter and cheese with products based on vegetable and plant oils). 
18.104.22.168 Inform people with RA who wish to try complementary therapies that although some may provide short-term symptomatic benefit, there is little or no evidence for their long-term efficacy. 
22.214.171.124 If a person with RA decides to try complementary therapies, advise them:
these approaches should not replace conventional treatment
this should not prejudice the attitudes of members of the multidisciplinary team, or affect the care offered. 
The Guideline Development Group (GDG) accepted a clinical diagnosis of rheumatoid arthritis (RA) as being more important than the 1987 American Rheumatism Association classification criteria for RA. This is because an early persistent synovitis in which other pathologies have been ruled out needs to be treated as if it is RA to try to prevent damage to joints. International committees are addressing the diagnostic criteria for early RA.
The GDG categorised RA into two categories: 'recent onset' (disease duration of up to 2 years) and 'established' (disease duration of longer than 2 years).
Rheumatoid arthritis with a duration of up to 2 years. Within recent-onset RA, categories of suspected persistent synovitis or suspected RA refer to patients in whom a diagnosis is not yet clear, but in whom referral to specialist care or further investigation is required.
To find out what NICE has said on topics related to this guideline, see our web page on arthritis.
 Such as managing negative thinking.
 For example, because of comorbidities or pregnancy, during which certain drugs would be contraindicated.
 These recommendations are from 'Anakinra for rheumatoid arthritis', NICE technology appraisal guidance 72. The GDG reviewed the evidence on anakinra but made no changes to the recommendations.
 Cosmetic improvements should not be the dominant concern.
 For example, paraesthesiae, weakness, unsteadiness, reduced power, extensor plantars.
 Arnett FC, Edworthy SM, Bloch DA et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis & Rheumatism 31(3): 315–24.